FindTrial
Sign In

Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia

Studying the Expected Effect of Ivermectin Nanosuspension as Nasal Spray Upon Post covid19 Persistant Anosmia

Status
UNKNOWN
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04951362
Enrollment
117
Registered
2021-07-06
Start date
2021-04-20
Completion date
2022-05-15
Last updated
2022-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anosmia

Brief summary

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

Detailed description

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia as one of the most characteresic symptoms of covid19 infection

Interventions

DRUGintranasal spray ivermectin

intranasal spray of saline

Sponsors

South Valley University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* post covid19 anosmia * negative swab test for covid19

Exclusion criteria

* other types of anosmia , * no local or central other causes of anosmia * still active covid 19 pateints ( positive swab test )

Design outcomes

Primary

MeasureTime frameDescription
regaining of smellwithin 14 days after enrollemen ]regaining of smell

Countries

Egypt

Contacts

Primary ContactZaky Aref, MD
doctor.aref@hotmail.com+201001771210

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026